Latest Healthcare Research Reports

Tag: ranibizumab market size

Unlocking the Future of the Ranibizumab Market: Growth Rate, Key Trends, and Opportunities for 2025-2034

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Analyzing the Growth Rate of the Ranibizumab Market: What’s the Expected CAGR for the Next Decade?

Over the past few years, the ranibizumab market has seen consistent growth. The market will experience an increase from $2.66 billion in 2024 to $2.78 billion in 2025, with a compound annual growth rate (CAGR) of 4.6%. Reasons contributing to the growth during the historic period include the scaling up of clinical trials in developing markets, the rising incidence of age-related macular degeneration (AMD), amplified awareness about retinal diseases, an increased number of diabetic retinopathy cases, government initiatives and funding, as well as elevated healthcare expenditure.

Expectations for the ranibizumab market project a consistent expansion in the coming years, anticipating an escalation to $3.3 billion by 2029 with a 4.3% compound annual growth rate (CAGR). The expected growth during the forecast period is connected to ongoing research and development, the entrance of biosimilars, an amplified focus on combined therapies, the growth of teleophthalmology, extended indications for ranibizumab application, and beneficial reimbursement policies. Significant trends during the forecast period encompass biotechnological advancements, innovative progress in medicine delivery systems, a move towards bespoke medicine, the rising use of artificial intelligence in ophthalmology, the formulation of extended-acting drugs, and a surge in the adaptation of patient-focused care models.

What Are the Primary Drivers Supporting the Growth of the Ranibizumab Market?

The escalating incidence of eye-related illnesses is anticipated to fuel the expansion of the ranibizumab market. This pertains to a broad spectrum of conditions that could potentially hamper eye health and vision. The surge in eye diseases can be attributed to aging demographics, lifestyle modifications, and a rise in chronic illnesses like diabetes. Ranibizumab is utilized to address conditions such as age-related macular degeneration and diabetic retinopathy, contributing to the mitigation of vision impairment given the escalating incidence of eye diseases. For instance, as per the World Health Organization (WHO), a Switzerland-based intergovernmental organization, in August 2023, around 2.2 billion individuals globally suffered from either near or distance vision impairment. Therefore, the escalating incidence of eye-related illnesses will stimulate the expansion of the ranibizumab market.

Get Your Free Sample of the Global Ranibizumab Market Report Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

What Are the Leading Organizations Impacting the Ranibizumab Market’s Growth?

Major companies operating in the ranibizumab market are:

• F. Hoffmann-La Roche AG

• Bayer AG

• Novartis AG

• Teva Pharmaceutical Industries Ltd

• Regeneron Pharmaceuticals Inc.

What Are the Most Prominent Trends Driving Change in the Ranibizumab Market?

Leading players in the ranibizumab market are concentrating their efforts on developing cost-efficient solutions such as ranibizumab biosimilars, aiming to address and halt vision deterioration in those with retinal disorders. A ranibizumab biosimilar is a biological medicine that shares a high level of similarity with the original ranibizumab, though it’s sold under another brand, offering an equally effective and safe but less expensive substitute. For example, in April 2024, Formycon AG, a biotechnology firm from Germany, and Bioeq AG, a biopharmaceutical company from Switzerland, unveiled the joint commercial deployment of FYB201, a Lucentis (Ranibizumab) biosimilar, in Canada and Switzerland. This introduction was made possible by the marketing permissions granted by Health Canada under the brand Ranopto and Swissmedic under the brand Ranivisio. FYB201 presents a fresh, high-grade, efficient, and budget-friendly remedy for individuals suffering from severe retinal diseases and has proven its worth as a financially sensible alternative for patients in the USA and different regions of Europe.

Get Instant Access to the Global Ranibizumab Market Report with Swift Delivery!

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Which Key Segments of the Ranibizumab Market Are Poised for Growth and Innovation?

The ranibizumab market covered in this report is segmented –

1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial

2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants

2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants

What Regions Are Leading the Charge in the Ranibizumab Market?

North America was the largest region in the ranibizumab market in 2024. The regions covered in the ranibizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Parameters Define the Ranibizumab Market’s Scope?

Ranibizumab is a recombinant humanized monoclonal antibody fragment designed to inhibit the activity of vascular endothelial growth factor A (VEGF-A) in the treatment of various retinal conditions by reducing abnormal blood vessel growth and leakage in the eye. Its advantage lies in its targeted delivery via intravitreal injection, minimizing systemic side effects while preserving and potentially improving vision in affected patients.

Browse Through More Similar Reports By The Business Research Company:

Nivolumab Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/nivolumab-global-market-report

Trastuzumab Biosimilars Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/trastuzumab-biosimilar-global-market-report

Anatomic Pathology Equipment and Consumables Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/anatomic-pathology-equipment-and-consumables-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

February 24, 2025
Key Highlights of the Lucentis (Ranibizumab) Market 2025-2034: Growth Dynamics, Trends, and Opportunities

Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

What is the Forecasted Expansion Rate of the Lucentis (Ranibizumab) Market Over the 2025–2034 Period?

Recently, the market size for lucentis (ranibizumab) has seen robust growth. It is expected to expand from $3,538.57 million in 2024 to $3,741.97 million in 2025, rising at a compound annual growth rate (CAGR) of 5.7%. The growth experienced in the historical period may be due to an increase in the prevalence of age-related macular degeneration (AMD), approvals and coverages by regulatory bodies, demonstrated efficacy and clinical outcomes, strong brand acknowledgement and endorsement by physicians, the emergence of biosimilars, and competitive pricing.

The market size of Lucentis (Ranibizumab) is projected to experience robust expansion in the ensuing years. The market is set to surge to $4,633.35 million in 2029, boasting a Compound Annual Growth Rate (CAGR) of 5.5%. This upturn forecasted in the coming period can be associated with rising cases of diabetic retinopathy (DR) and diabetic macular edema (DME), advancements in treatment strategies and combined therapies, an aging demographic along with an escalating frequency of retinal ailments, the widening of market reach in burgeoning economies, continuous clinical studies, and potential new applications. Key trends anticipated in the forecast period comprise a shift toward more extended-interval dosing and maintenance treatment, increasing adoption of biosimilars and alternative therapies, a surge in personalized medical

approaches for retinal diseases, burgeoning demand in emerging markets due to improved healthcare accessibility, and incorporation of digital health solutions in treatment monitoring.

What Industry-Specific Factors Are Fueling the Growth of the Lucentis (Ranibizumab) Market?

An increase in eye-related disorders is predicted to fuel the Lucentis (ranibizumab) market’s expansion. These disorders consist of a multitude of diseases or conditions that impact the eyes, hindering their normal function. Factors contributing to the rise of eye-associated disorders include aging, genetic factors, harmful lifestyle decisions like smoking and improper diet, and environmental factors like extended exposure to sun or digital screens. Lucentis operates by constraining the vascular endothelial growth factor (VEGF), a protein that causes abnormal blood vessel expansion and leakage in the retina, a major reason for conditions such as age-related macular degeneration (AMD) and diabetic macular edema (DME). To illustrate, the National Eye Institute, a US governmental agency, projected that by 2030, 2.2 million Americans will be blind. As a result, the growth of the Lucentis (ranibizumab) market is being propelled by the increasing prevalence of eye-related disorders.

Request Your Free Lucentis (Ranibizumab) Market Report Sample Now!

https://www.thebusinessresearchcompany.com/sample.aspx?id=19907&type=smp

Who Are the Leading Organizations Fueling the Expansion of the Lucentis (Ranibizumab) Market?

Major companies operating in the lucentis (ranibizumab) market include F.Hoffmann-La Roche Ltd, Novartis AG

Which Cutting-Edge Trends Are Expected to Drive the Lucentis (Ranibizumab) Market’s Growth?

A core movement in the Lucentis (ranibizumab) market is the creation of biosimilars to offer cost-effective options to the original brand-name product. Biosimilars are biologic medical items that closely mirror already approved reference biologics in structure, efficiency, and safety, without any significant clinical variations. To illustrate, Formycon AG, a biotech firm from Germany, and Switzerland’s Bioeq AG initiated the release of their biosimilar version of Lucentis (ranibizumab), dubbed FYB201, in Canada and Switzerland in April 2024. The biosimilar received market authorization from Health Canada under the moniker Ranopto, while Swiss Medic gave their approval with the label Ranivisio. The green light and subsequent implementation of FYB201 purports to offer more economically feasible treatment routes for those battling retinal ailments. This product works by impeding vascular endothelial growth factor A (VEGF-A), a protein that encourages abnormal blood vessel development in the retina, potentially leading to swelling, leakage, and weakened vision.

Pre-order Your Report for Quick and Easy Delivery!

https://www.thebusinessresearchcompany.com/report/lucentis-ranibizumab-global-market-report

What Are the Key Components of the Lucentis (Ranibizumab) Market, and How Do Its Segments Perform?

The lucentis (ranibizumab)market covered in this report is segmented –

1) By Type: Single-use Prefilled Syringe; Single-use Glass Vial

2) By Application: Age-related Macular Degeneration; Diabetic Retinopathy; Retinal Vein Occlusion; Myopic Choroidal Neovascularization; Uveitis

3) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users

Which Regions Are Most Influential in Expanding the Lucentis (Ranibizumab) Market?

North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lucentis (ranibizumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Does the Definition of the Lucentis (Ranibizumab) Market Include?

Lucentis (ranibizumab) is a prescription medication used to treat various eye disorders, those involving abnormal blood vessel growth in the retina. It is a recombinant monoclonal antibody fragment designed to inhibit vascular endothelial growth factor (VEGF), a protein that promotes the formation of abnormal blood vessels.

Browse Through More Similar Reports By The Business Research Company:

Retinal Vein Occlusion Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/retinal-vein-occlusion-global-market-report

Retinal Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/retinal-biologics-global-market-report

Uncomplicated Urinary Tract Infection Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/uncomplicated-urinary-tract-infection-treatment-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

February 18, 2025
Ranibizumab Market Forecast 2024-2033: Anticipated Size and Growth Trends

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Ranibizumab Market from 2024 to 2033?
The ranibizumab market is projected to rise from $2.55 billion in 2023 to $2.66 billion in 2024, with a CAGR of 4.3%. This growth is linked to the expansion of clinical trials in emerging markets and the rising prevalence of age-related macular degeneration (AMD).

Ranibizumab Market: The ranibizumab market is forecasted to experience steady growth, reaching $3.16 billion by 2028 at a CAGR of 4.4%. Factors driving this growth include ongoing R&D, the introduction of biosimilars, a focus on combination therapies, advancements in teleophthalmology, expanded indications, and favorable reimbursement policies. Major trends include biotechnology advancements, innovations in drug delivery, personalized medicine, and patient-centric care models.

Claim Your Free Sample of the Global Ranibizumab Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

What Key Factors Are Fueling the Growth of the Ranibizumab Market?
The rising incidence of eye diseases is anticipated to fuel the growth of the ranibizumab market. Eye diseases include various conditions that can impair vision and eye health, driven by aging populations, lifestyle changes, and a rise in chronic conditions such as diabetes. Ranibizumab is utilized to treat conditions like age-related macular degeneration and diabetic retinopathy, which helps mitigate vision impairment amid the increasing prevalence of eye diseases. For example, the International Agency for the Prevention of Blindness (IAPB) projected in February 2021 a 55% increase in vision loss by 2050, with those affected expected to rise from 1.106 billion in 2020 to 1.758 billion by 2050. Therefore, the growing prevalence of eye diseases will stimulate the ranibizumab market.

What Are the Major Segments of the Ranibizumab Market?
1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial
2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

What New Trends Are Transforming the Ranibizumab Market?
Companies in the ranibizumab market are focusing on cost-effective therapies, including biosimilars, to help treat retinal disorders. In April 2024, Formycon AG and Bioeq AG announced the launch of FYB201, a biosimilar to Lucentis, providing an affordable treatment option in Canada and Switzerland.

Order Now for Fast Delivery of Your Ranibizumab Market Report!
https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Which Regions Are Driving Growth in the Ranibizumab Market?
North America was the largest region in the ranibizumab market in 2023 The regions covered in the ranibizumab market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Ranibizumab Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the ranibizumab market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Ranibizumab Market Include

1. Ranibizumab Market Executive Summary
2. Ranibizumab Market Segments
3. Ranibizumab Market Size And Template Market Growth Rate
4. Key Ranibizumab Market Trends
5. Major Ranibizumab Market Drivers
……
25. Key Mergers And Acquisitions In The Ranibizumab Market
26. Top Ranibizumab Companies
27. Ranibizumab Market Opportunities And Strategies
28. Ranibizumab Market, Conclusions And Recommendations
29. Appendix

Discover Related Reports by The Business Research Company:
Pet Food Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/pet-food-global-market-report

Anatomic Pathology Equipment And Consumables Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/anatomic-pathology-equipment-and-consumables-global-market-report

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/adalimumab-infliximab-and-etanercept-biosimilar-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

October 24, 2024
How Is The Ranibizumab Market Expected To Grow Through 2024-2033
The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Ranibizumab Global Market Report 2024, the ranibizumab market is expected to show promising growth in the forecast period.

The ranibizumab market has experienced steady growth in recent years and is poised for further expansion. Here’s an overview of the market trends, drivers, and key players shaping its future.

Market Growth Overview
- Current Market Size: The ranibizumab market was valued at $2.55 billion in 2023.
- 2024 Projections: Expected to grow to $2.66 billion, reflecting a compound annual growth rate (CAGR) of 4.3%.
- Future Outlook: Anticipated to reach $3.16 billion by 2028, with a CAGR of 4.4%.
Factors Driving Market Growth
- Expansion of Clinical Trials: Increased clinical trials in emerging markets are contributing to market growth.
- Rising Prevalence of AMD: The growing incidence of age-related macular degeneration (AMD) is driving demand for ranibizumab.
- Awareness and Government Initiatives: Enhanced awareness about retinal diseases and supportive government funding and initiatives are boosting the market.
- High Incidence of Diabetic Retinopathy: With rising cases of diabetic retinopathy, the need for effective treatments like ranibizumab is increasing.
- Healthcare Expenditure: Growing healthcare spending is also a significant factor in the market’s expansion.
View More On The Ranibizumab Market Report 2024 – https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Future Growth Drivers
- Ongoing Research and Development: Continued R&D efforts are expected to foster growth.
- Introduction of Biosimilars: The launch of biosimilars is providing cost-effective alternatives, stimulating market growth.
- Combination Therapies: Increased focus on combination therapies is expected to drive demand.
- Teleophthalmology and Expanded Indications: Growth in teleophthalmology and the widening indications for ranibizumab will contribute to market expansion.
- Favorable Reimbursement Policies: Improved reimbursement policies are likely to support market growth.
Major Trends in the Forecast Period
- Advancements in Biotechnology: Innovations in biotechnology are set to enhance treatment options.
- Technological Innovations in Drug Delivery: Advances in drug delivery systems are expected to improve treatment efficacy.
- Shift Towards Personalized Medicine: A growing emphasis on personalized medicine is likely to drive market growth.
- Use of Artificial Intelligence: The increasing application of AI in ophthalmology is transforming the landscape.
- Development of Longer-Acting Formulations: The development of longer-acting formulations will provide patients with more effective treatment options.
- Patient-Centric Care Models: A rise in patient-centric care models is expected to influence market dynamics positively.
Impact of Global Eye Disease Rise
- Increasing Prevalence: The global rise in eye diseases, driven by aging populations and lifestyle changes, is a key market driver.
- Projected Vision Loss: According to the International Agency for the Prevention of Blindness (IAPB), vision loss is projected to increase significantly by 2050, driving demand for treatments like ranibizumab.
- Conditions Treated: Ranibizumab is used for treating AMD, diabetic retinopathy, and other retinal disorders, addressing the growing need for effective therapies.
Key Market Players
- Leading Companies: Major players in the ranibizumab market include F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Teva Pharmaceutical Industries Ltd, Regeneron Pharmaceuticals Inc., Biogen Inc., and others.
- Biosimilar Initiatives: Companies like Formycon AG and Bioeq AG have launched biosimilars, such as FYB201, offering affordable alternatives to the original ranibizumab.
Strategic Acquisitions
- Sandoz and Coherus BioSciences: In March 2024, Sandoz acquired Coherus BioSciences’ CIMERLI business to enhance its biosimilar offerings in ophthalmology, highlighting the strategic moves within the market.
Market Segmentation
- By Product: Includes Single Use Prefilled Syringe and Single Use Glass Vial.
- By Application: Covers Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), and Retinal Vein Occlusion (RVO).
- By Distribution Channel: Includes Hospital Pharmacies, Online Pharmacies, and Other Distribution Channels.
Regional Insights
- North America: Dominated the ranibizumab market in 2023 and continues to be a key region for market expansion.
The ranibizumab market is set for continued growth, driven by increasing eye disease prevalence, advancements in technology, and the introduction of cost-effective biosimilars. Major companies are adapting to these trends, positioning themselves for future success in this evolving market.

Request A Sample Of The Global Ranibizumab Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=16172&type=smp
July 24, 2024